Summary Background DNA aptamers represent a novel strategy in anti-cancer medicine. AS1411, a DNA aptamer targeting nucleolin (a protein which is overexpressed in many tumor types), was evaluated in patients with metastatic, clearcell, renal cell carcinoma (RCC) who had failed treatment with ≥1 prior tyrosine kinase inhibitor. Methods In this phase II, single-arm study, AS1411 was administered at 40 mg/kg/ day by continuous intravenous infusion on days 1-4 of a 28-day cycle, for two cycles. Primary endpoint was overall response rate; progression-free survival (PFS) and safety were secondary endpoints. Results 35 patients were enrolled and treated. One patient (2.9 %) had a response to treatment. The response was dramatic (84 % reduction in tumor burden by RECIST 1.0 criteria) and durable (patient remains free of progression 2 years after completing therapy). Whole exome sequencing of this patient's tumor revealed missense mutations in the mTOR and FGFR2 genes which is of interest because nucleolin is known to upregulate mTOR pathway activity by enhancing AKT1 mRNA translation. No other responses were seen. Thirty-four percent of patients had an AS1411-related adverse event, all of which were mild or moderate. Conclusions AS1411 appears to have minimal activity in unselected patients with metastatic RCC. However, rare, dramatic and durable responses can be observed and toxicity is low. One patient in this study had an excellent response and was found to have FGFR2 and mTOR mutations which will be of interest in future efforts to discover and validate predictive biomarkers of response to nucleolin targeted compounds. DNA aptamers represent a novel way to target cancer cells at a molecular level and continue to be developed with a view to improving treatment and imaging in cancer medicine.
Introduction
Within the USA each year, more than 55,000 people are diagnosed with renal cell carcinoma and more than 10,000 die of the disease [1] . While the treatment of localized RCC by complete or partial nephrectomy is potentially curative, current therapies for metastatic RCC are generally palliative. Presently, the expected median survival for patients with metastatic or inoperable locally-advanced RCC is approximately 24 months [2] .
Agents that target angiogenesis or mammalian target of rapamycin (mTOR) pathways have resulted in longer survival in several studies, although they often are associated with multiple toxicities and ultimately drug resistance is universal [3] [4] [5] [6] . Therefore, a need remains to develop new agents in this clinical setting.
D N A a p t a m e r s a r e s ho r t s eq u e nc e s o f D N A (oligonucleotides) that have protein binding (aptameric) effects via shape specific recognition of a target protein in an interaction which is analogous to antibody-antigen binding. This property is thought to be due to the propensity of these molecules to form quadruplex structures rather than the usual double helix structure of DNA ( Fig. 1 ) [7] . Unlike some monoclonal antibodies however, these molecules are not associated with allergic infusion reactions because they are not immunogenic [8] . AS1411 is a first-in-class quadruplex DNA aptamer formed from a single-stranded, G-rich, phosphodiester, 26-mer oligonucleotide. It targets nucleolin, a multifunctional protein located primarily in the nucleolus, but also found in the cytoplasm and cell membrane [9] . The function of nucleolin varies depending on its cellular location. On the cell surface, it serves as a receptor for multiple ligands including growth factors and microorganisms [10] . In the cytoplasm it shuttles proteins into the nucleus and is involved in posttranscriptional regulation of strategic mRNAs [10] . In the nucleolus it regulates transcription and translation of key cancer related proteins including p53, Rb, bcl-2 and Akt-1 [9] [10] [11] . Nucleolin is overexpressed in many types of cancer [11] . AS1411 appears to bind to cell surface nucleolin and the AS1411-nucleolin complex is internalized which leads to inhibition of DNA synthesis [12, 13] . In cell line studies, the antiproliferative activity of AS1411 correlates directly with the extent to which the tumor cells are arrested in S phase which supports this hypothesis as the dominant mode of action [13] . This may be due to binding of the complex with nuclear factor-κB essential modulator, thereby preventing nuclear factor-κB activation and cell growth signaling [14] . Another mode of action may be destabilization of bcl2 mRNA with subsequent induction of apoptosis [14] .
AS1411 has shown some anti-tumor activity in patients with metastatic RCC in a prior phase I study in patients with solid tumors. At doses ranging from 1 to 40 mg/kg/day given as 4-or 7-day continuous intravenous infusions for up to two cycles of treatment, AS1411 produced one complete response (CR) and one partial response (PR) among 12 patients with metastatic RCC. Seven patients had stable disease (SD) of ≥2 months' duration [15] . No dose-limiting toxicity was observed, and it appeared that AS1411 might represent a less toxic alternative to current treatments. The aim of the present study was to confirm these promising signs of efficacy through a more formal evaluation. Based on previous data showing anti-tumor efficacy in RCC with only 1-2 cycles, Fig. 1 This figure shows the molecular models for the classic double helix "duplex" DNA and for "quadruplex" DNA. AS1411 has been shown to form a quadruplex and the quadruplex shown is one possible conformation of the human telomere sequence (PDB accession code 143d). The quadruplex structure is believed to allow DNA aptamers to act as ligands at cell surface receptors in an interaction which is analogous to antigen-antibody binding. and the complexity of DNA aptamer manufacture, only two cycles of therapy were administered.
Materials and methods

Study population
Patients aged 18 years and older, with histologically or cytologically-confirmed metastatic or locally advanced RCC containing predominantly clear-cell histology, who had already received ≥1 approved tyrosine kinase inhibitor, were eligible for enrolment if they satisfied the following criteria: prior nephrectomy; at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors v1 (RECIST) [16] ; Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; adequate bone marrow, hepatic and renal function; and a negative pregnancy test (with adequate contraception for women of childbearing potential). This trial was conducted prior to the commercial availability of everolimus.
Patients meeting any of the following criteria were excluded from the study: collecting duct, papillary, or chromophobe histology; brain metastases if patients were symptomatic or had received steroids for the brain lesions within 2 weeks of study entry; treatment with a non-approved or investigational product within 4 weeks of starting study therapy; treatment with an approved product within 2 weeks of the starting study therapy; breastfeeding; history of prior or concomitant malignancy (except for nonmelanoma skin cancer, carcinoma in situ of the cervix, or any other cancer from which the patient had been disease free for 3 years); any concurrent medical/ psychological condition that would limit ability to provide informed consent or compliance.
Patients were recruited into the study at seven study centers in the USA. The study was approved by local institutional review boards and conducted in accordance with the Declaration of Helsinki and its amendments. All patients gave written, informed consent before study entry.
Study design
In this open-label, single-arm, study patients received AS1411 40 mg/kg/day by continuous intravenous infusion on days 1-4 of a 28-day cycle, for two cycles. For toxicity ≥ grade 3 (according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 [NCI-CTCAE]), related to AS1411, the current infusion cycle was to be terminated immediately and not recommenced. If toxicity occurred during the first treatment cycle, the relevant adverse events (AEs) were to be followed until resolution or significant improvement before initiation of the second treatment cycle. Dose reduction was permitted in the second cycle for management of drug-related toxicities. Permanent discontinuation of study treatment was required in the event of disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, investigator decision, or sponsor request.
Assessments
Tumor response was evaluated using RECIST criteria and categorized as CR, PR, SD or progressive disease (PD). Tumor measurements using CT or MRI imaging were obtained at the screening visit and then every 8 weeks from start of treatment until disease progression. In addition to investigator assessments of tumor response, copies of tumor images were submitted for blinded independent assessment (BioClinica Inc., Newtown, PA, USA).
Patients underwent safety assessments with clinical, laboratory and 12 lead electrocardiogram monitoring at weekly intervals throughout treatment. Thereafter patients were assessed bimonthly to end of follow-up.
Pharmacokinetic (PK) studies using blood samples were performed to assess the area under the AS1411 plasma concentration-time curve during cycle 1. The C max (maximum observed plasma AS1411 concentration), C ss (plasma AS1411 concentration at steady state) and t ½ , (terminal elimination half-life) were also measured.
Statistical analysis
The primary efficacy endpoint was overall response rate (ORR; the proportion of patients reporting a best overall response of CR or PR). The null hypothesis (that the ORR for patients treated with AS1411 would be <5 %) was tested using a binomial test at an alpha level of 5 %. The response rate estimate is presented with a two-sided 95 % confidence interval (CI) using the Clopper-Pearson method. A one-sided 95 % CI corresponding to the test of the null hypothesis is also presented. Enrollment of 30 patients into the study was required to ensure 27 evaluable patients (assuming that 10 % would not be evaluable for response).
The secondary efficacy endpoints were progression free survival (PFS, defined as the time from the date of first infusion of AS1411 to the date of documented progression or death from any cause), time to progression (TTP, defined as the time from the date of first infusion of AS1411 until documented progression), duration of overall response (defined as the time from the first occurrence of CR or PR until the date of first documented disease progression or death) and duration of SD (defined as the time from the date of first infusion of AS1411 to the date of the first documented disease progression or death).
For PK analysis, plasma AS1411 concentration data was plotted using WinNonlin® version 5.2 (Pharsight, Mountain View, CA, USA) or Microsoft® Excel version 2003 SP3. PK evaluations were based on plasma AS1411 concentrations determined using a validated high-performance liquid chromatography procedure with photodiode array detection. PK variables were estimated using the WinNonlin® noncompartmental model 202.
Whole exome sequencing of tumor DNA
In an effort to identify unique somatic alterations that might explain the dramatic and durable response in one patient we performed whole exome sequencing of DNA from that patient's tumor. DNA was extracted from the patient's archival formalinfixed, paraffin-embedded tumor sample and adjacent normal tissue using Qiagen QIAamp DNA FFPE Tissue Kit Quantitation Reagent (Invitrogen). Whole exome sequencing was performed from 100 nanograms of DNA from tumor and normal tissue using the Illumina HiSeq platform with established protocols [17] . A BAM file aligned to the hg19 human genome build was created using Illumina reads and the Picard pipeline at the Broad institute (http://www.broadinstitute.org/gatk/). Subsequent analysis of the BAM files was performed using the Firehose infrastructure (http://www.broadinstitute.org/cancer/cga/ Firehose) . The MuTect algorithm was applied to identify somatic single-nucleotide variants in targeted exons [18] . Indelocator was used to identify small insertions or deletions (http://www.broadinstitute.org/cancer/cga/indelocator).
Results
Patient disposition and exposure to AS1411
A total of 37 patients with RCC were enrolled, of whom 35 received AS1411, thereby constituting the full treatment and safety analysis sets. Of these, all 35 patients received the first cycle of AS1411, while 33 (94.3 %) received the second cycle of AS1411; two (5.7 %) patients failed to receive both cycles because of disease progression. The per protocol analysis set consisted of 34 patients; the patient excluded from this set withdrew consent after completion of the second AS1411 infusion cycle but without having undergone any postbaseline tumor assessment to evaluate response.
Baseline characteristics
Baseline characteristics of patients in the full analysis set are summarized in Table 1 . Median age was 61 (range 39-81) and 14 patients (40 %) were aged ≥65 years. Previous anticancer treatments are summarized in Table 2 . All patients had undergone nephrectomy for RCC and had received ≥1 tyrosine kinase inhibitor. The median number of prior systemic therapies received was 2 (range 1-7).
Safety
No deaths occurred during the study treatment period and no death was assessed as being related to AS1411 therapy.
All patients had ≥1 treatment-emergent AE. Most patients (80 %) had only mild or moderate AEs (grade 1 or 2). Seven patients (20 %) had severe AEs (grade 3). Constipation, fatigue, and peripheral edema were the most common AEs (Table 3) . Anemia, hyperglycemia and hypoalbuminemia were the most common laboratory abnormalities (Table 4) . Twelve (34 %) patients had AEs that were judged by the investigator as being related to AS1411; all were grade 1 or 2, and only headache (n =3), increased aspartate aminotransferase (AST) (n =2), and fatigue (n =2) were reported with greater than single patient incidence.
Five (14 %) patients reported serious AEs, none of which was judged by the investigator as being related to AS1411.
Efficacy
One patient had a PR, resulting in an ORR of 2.9 % ( Table 5 ). The response was dramatic (84 % reduction in the sum of longest diameters of selected target tumor lesions) and durable (patient remains free of progression 2 years after completing therapy). The two-sided 95 % CIs for response rate and their associated p-values (full analysis set, 0.1-14.9 %; per protocol analysis set, 0.1-15.3 %) did not permit rejection of the null hypothesis that the ORR for patients treated with AS1411 is <5 %. Secondary efficacy endpoints for patients in the full analysis set are also summarized in Table 5 . Median PFS was 2 months (95 % CI 1.8-3.8) as determined by investigator assessment and 4 months (95 % CI 2.0-8.7) by independent review. Median duration of SD was 5.5 months (95 % CI 3.8-5.8) based on investigator assessment and 5.8 months (95 % CI 5.8-8.7) months based on independent assessment. As a treatment response was reported for only one patient, no formal analysis of duration of overall response was possible; however this patient currently remains free of progression 2 years after completion of study therapy.
Pharmacokinetics
Summary PK variables derived from plasma AS1411 concentrations during and after continuous infusion are shown in Table 6 . There was large variability in plasma AS1411 concentrations between patients. After the cessation of infusion, the plasma AS1411 concentration declined rapidly in a monophasic manner. The disposition of AS1411 followed linear kinetics. The estimated mean systemic CL of 111± 40.9 mL/h/kg was approximately the same as the glomerular filtration rate of 107 mL/h/kg, suggesting renal filtration as the major clearance route. V ss ranged from 38.0 to 2520 mL/kg and was highly variable between patients (CV%, 94.2); this may indicate different distribution patterns in different patients.
The mean C ss of 20.6±7.00 μg/mL was similar to the IC 50 concentration identified for renal cancer cell lines in vitro. Exposure to AS1411 in the patient with a PR, as assessed by C max , C ss , and AUC, was similar to that in other patients, indicating that the response observed in this patient was not a result of greater exposure to the study drug.
Exome sequencing of tumor DNA from the responding patient Mean target coverage for the tumor and normal samples were 57X and 40X, respectively. Somatic missense mutations of the fibroblast growth factor receptor 2 (FGFR2, A371V) and mTOR (E1485K) genes were identified. These mutations were in the 3 rd immunoglobulin-like and FAT domains respectively [19, 20] . The von Hippel-Lindau gene (VHL) was not somatically mutated. Table 7 outlines the full list of missense exon coding mutations and indels identified in this tumor.
Discussion
We present the first manuscript reporting the use of this novel anti-cancer agent in humans.
In an open-label, single-arm, multicenter, phase II study, we investigated the efficacy and safety of the DNA aptamer AS1411 in the treatment of patients with advanced RCC who had failed tyrosine kinase inhibitor therapy.
Although only one patient achieved a PR (ORR 2.9 %), this was a dramatic response to treatment with an 84 % decrease in the sum diameters of target tumor lesions. That patient remains in PR at 24 months from the end of study therapy with no evidence of disease progression and no requirement for additional therapy. Interestingly, this patient was primary refractory to prior TKI therapies. The durability of this response may lead one to suspect an immune driven mode of action. However, there were no signs of constitutive immune activation either clinically (no rash, pruritis or other autoimmune phenomena) or on laboratory testing (leukocyte and lymphocyte counts were within normal range with no marked elevations after starting therapy). Whole exome sequencing of tumor DNA from this patient revealed a somewhat unusual mutation profile in that there were no mutations in the most commonly mutated genes in RCC, namely VHL and the chromatin/histone remodeling genes PBRM1, SETD2 and BAP1 [19] [20] [21] . ARID1B, a SWI/SNF chromatin remodeling complex protein was mutated and there were also missense mutations in mTOR and FGFR2 which are rare in RCC (6 % and <1 % of cases respectively) [21] . AKT1 is an upstream stimulator of mTOR pathway activity and nucleolin is known to upregulate this activity through mRNA translation enhancement [22] . Therefore, AS1411 may downregulate AKT/mTOR pathway activity in the setting of oncogene addiction to one or both of the aforementioned mutations and may lead to dramatic tumor response. Of course, such inferences are speculative since functional data is lacking, but this patient's mutation profile is noteworthy for the purposes of future research in the field. Of note, in the phase 1 study of AS1411 a similar dramatic response was seen in a patient with metastatic RCC who had a near CR to treatment of 18 months duration [15] .
Median PFS was 4 months by independent assessment and 2 months by investigator assessment. The marked differences between the independent and investigator reviews are different from what is usually expected, where investigator bias is associated with improved PFS rather than shorter PFS. Although this agent had limited activity in RCC it was well tolerated with minimal toxicity.
Despite the disappointing overall efficacy results in this trial, DNA aptamers remain promising molecules with potential utility in cancer medicine. Recently, a Her2 targeted DNA aptamer conjugated to doxorubicin was shown to selectively deliver this cytotoxic to Her2 overexpressing cancer cells in vitro [23] . Another study used AS1411 tagged drug-loaded nanoparticles to deliver targeted cytotoxic therapy to nucleolin overexpressing cancer cells in vitro with promising results [24] . Furthermore, the potential of AS1411 in novel cancer imaging techniques was shown in a study where it was conjugated to a magnetic fluorescence micro-RNA molecule which allowed cancer cell uptake and imaging of intracellularly expressed micro-RNA [25] .
The oncology community is increasingly aware that drugs which target specific molecular abnormalities within a tumor need to be restricted to patients with relevant signaling pathway aberrations to show their full potential [26, 27] . Such a strategy leads to improved risk-benefit and cost-benefit ratios for novel drugs. Molecular and genetic discoveries are demonstrating the heterogeneity of cancer and compartmentalizing it into "a thousand rare diseases" meaning such rational selection of appropriate patients will become increasingly relevant in future trials of novel agents [28] . Unfortunately, archival tissue was not routinely collected on this trial to allow retrospective analysis of the genetic profile and nucleolin expression in all patients.
In conclusion, this study along with the prior phase 1 trial provides evidence that although AS1411 has low response rates in unselected patients with metastatic RCC, dramatic and durable responses can be observed and toxicity is low [15] . It is difficult to draw firm conclusions from these rare responses but tumor profiling of the responder in this study revealed missense FGFR2 and MTOR mutations and this knowledge along with the other genetic data reported here may be relevant for future research in this area. DNA aptamers represent a novel way to target cancer cells at a molecular level and continue to be developed with a view to improving treatment and imaging in cancer medicine.
